GRAYBUG VISION(GRAY-T) - 2025 Q4 - Annual Results

Exhibit 99.1 CalciMedica Reports 2025 Financial Results and Provides Clinical Updates Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipat ...